diagnostics

Poka Cui and colleagues completed a literature review along with interviews involving lung cancer multidisciplinary teams from 24 medical centers across Europe and Canada. In this report, they also introduce a comprehensive self-assessment...

Poka Cui and colleagues...

02/09/2024

Journal of Clinical Pathways

News

Predicting Clinical Outcomes of Patients With High-Risk MCL

06/18/2020

Patients with high-risk mantle cell lymphoma (MCL) biology—defined by blastoid variance, Ki-67 greater than 30%, or high p53 immunohistochemistry expression—are more likely to experience shorter failure-free and...

...

06/18/2020

Journal of Clinical Pathways

News

NCCN Biomarker Guideline Adherence Linked With Decreased Mortality in NSCLC

06/16/2020

Adherence to the National Comprehensive Cancer Network (NCCN) guideline for biomarker testing for non-squamous advanced non-small cell lung cancer (NSCLC) is associated with decreased risk of mortality, according to a recent...

Adherence to the National...

06/16/2020

Journal of Clinical Pathways

Pharma Insights

Could the Lack of an Efficient and Affordable Diagnostic Pathway Limit Market Access for New Alzheimer`s Treatments?

06/20/2016

Rick Lifsitz , MBA;

Larry Blandford , PharmD;

The promise in the coming years of a novel therapeutic to slow the progression of the debilitating effects of Alzheimer’s disease (AD) is exciting and represents a monumental step forward in treating patients with...

The...

06/20/2016

Journal of Clinical Pathways

Research in Review

SERS Nanoprobes Help to Identify and Distinguish NSCLC Subtype

01/15/2016

JCP Editors

Chinese researchers have created an effective method for identifying and distinguishing non–small lung cancer (NSCLC) subtypes, utilizing nanotechnology in conjunction with statistical methods. The field of...

...

01/15/2016

Journal of Clinical Pathways